| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
当 Tranylcypromine (SKF 385) (GMP) 和 Laduviglusib 联合使用时，由 Oct4 和 Klf4 两种因子转导的人原代角质形成细胞会发生重编程 [2]。
|
|---|---|
| 体内研究 (In Vivo) |
在野生型小鼠中，盐酸反苯环丙明（3 mg/kg；腹腔注射；每天一次，持续三天）可降低促炎细胞因子 COX-2 和 IL-6 水平以及 LPS 介导的小胶质细胞激活[3]。在 5xFAD 小鼠中，盐酸反苯环丙明（3 mg/kg；腹腔注射；每天一次，持续 7 天）可减少 Aβ 介导的小胶质细胞激活[3]。
|
| 动物实验 |
Animal/Disease Models: Wild-type mice[3]
Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 3 days Experimental Results: Dramatically down-regulated LPS-stimulated microglial activation in the cortex and Hippocampus, and LPS-induced astrocyte activation only in the cortex. decreased LPS-induced COX-2 levels in hippocampus CA1, diminished LPS-evoked IL-6 levels in the cortex and hippocampus CA1 and suppressed LPS-mediated IL-1β levels in the cortex. Animal/Disease Models: 5xFAD mice[3] Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 7 days Experimental Results: Differentially regulated microglial and astrocyte activation in this mouse model of AD. |
| 参考文献 |
Drug Metab Dispos.2001 Jun;29(6):897-902;Environ Health Perspect.2004 Aug;112(11):1159-64.
|
| 分子式 |
C9H12CLN
|
|
|---|---|---|
| 分子量 |
169.65
|
|
| CAS号 |
1986-47-6
|
|
| 相关CAS号 |
|
|
| SMILES |
N[C@H]1[C@H](C2=CC=CC=C2)C1.[H]Cl
|
|
| InChi Key |
ZPEFMSTTZXJOTM-OULXEKPRSA-N
|
|
| InChi Code |
InChI=1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m0./s1
|
|
| 化学名 |
trans-2-Phenylcyclopropylamine Hydrochloride
|
|
| 别名 |
|
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8945 mL | 29.4724 mL | 58.9449 mL | |
| 5 mM | 1.1789 mL | 5.8945 mL | 11.7890 mL | |
| 10 mM | 0.5894 mL | 2.9472 mL | 5.8945 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01430455 | Completed Has Results | Drug: Tranylcypromine | Bipolar Disorder I or II | New York State Psychiatric Institute | November 2011 | Phase 4 |
| NCT00653393 | Completed | Drug: Tranylcypromine Drug: Parnate |
To Determine the Bioavailability of Tranylcypromine |
Par Pharmaceutical, Inc. | October 2004 | Phase 1 |
| NCT00296686 | Terminated | Drug: Tranylcypromine Drug: Dextroamphetamine |
Major Depression | New York State Psychiatric Institute | September 2001 | Phase 4 |
| NCT02273102 | Completed | Drug: Tranylcypromine Drug: Tretinoin |
Acute Myelogenous Leukemia Myelodysplastic Syndromes |
University of Miami | March 2, 2015 | Phase 1 |
|
|---|
|
|
Tioxolone
U-104
Tranylcypromine hemisulfate
Benzenesulfonamide (Benzenesulphonamide, Benzosulfonamide)
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
COA
粤公网安备 44011102003439号